Faron Pharmaceuticals Ltd: Special Rights attached to the First and Second Tranche of Bonds

▤ Summary

Faron Pharmaceuticals announced that its board approved the issuance of 8 million additional Special Rights tied to the first and second tranches of its bonds. The rights support future share issuance or cash amortisation obligations under the bond terms. The company said the special rights are directed to Heights Capital Management without shareholder pre-emptive rights and will transfer with the bonds if they are sold. The notice also restates information about Faron’s BEXMAB clinical trial and its lead immunotherapy bexmarilimab in AML and MDS.

▦ Linked Companies